Mithra Strengthens Position in the Belgian Contraception Market

  • Mithra builds on leading position in Belgian contraceptive market
  • Mithra achieves significant increase in 2016 sales
  • Market trend validates Mithra’s Estetrol-based programs

Liège, Belgium January 31, 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97% to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%.

Mithra Plans to Submit Myring for US and EU Approval in Q2 2017

Planned submissions follow successful trials demonstrating bioequivalence to NuvaRing®

Liège, Belgium, 24 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it intends to submit its combined hormonal contraceptive vaginal ring, Myring, for marketing approval in both Europe and the United States in Q2 2017.

Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive

Liège, Belgium, 18 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/238,310 a patent which covers the use of Estetrol (E4) as an emergency contraceptive.

Mithra’s North American Advisory Board for Donesta® Will Meet in Miami, Florida 20th- 21st January 2017

  • Mithra has set up scientific advisory boards composed of international experts to support the development of Donesta®, its product candidate for menopause based on Estetrol (E4).
  • The North American scientific advisory board, set up by Mithra, is aiming at gathering additional development guidance from international experts in the menopause field.

Mithra Announces 2017 Financial Calendar

Liège, Belgium 11 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2017.

  • 2 March 2017: Full Year Results 2016
  • 18 April 2017: Annual Report 2016
  • 18 May 2017: Annual General Meeting 2017
  • 12 September 2017: Half Year Results 2017

This schedule is indicative and subject to change.

The calendar is also available on Mithra’s Investor website: investors.mithra.com.

Publication of a Transparency Notification Received by Mithra Pharmaceuticals SA/NV

Liège, Belgium 09 January 2017 – Regulated information – In accordance with article 14 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA/NV publishes the following information:

Mithra Pharmaceuticals SA/NV has received a transparency notification dated 29 December 2016, which states that Bart Versluys (Versluys Invest BVBA, Versluys Bouwgroep BVBA), as a result of the net purchase of shares, now has 3,28% of the voting rights in Mithra Pharmaceuticals SA/NV (total number of voting rights : 31.129.756) and as a consequence, crossed the reporting threshold of 3%.

Appointment of Christophe Maréchal as Chief Financial Officer

Liège, Belgium, 6 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces the appointment of Christophe Maréchal as Chief Financial Officer (CFO) with effect from 23 February 2017.